Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells 117,351 Shares of Stock

Adaptive Biotechnologies Co. (NASDAQ:ADPTGet Free Report) CEO Chad M. Robins sold 117,351 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.98, for a total transaction of $819,109.98. Following the completion of the transaction, the chief executive officer now directly owns 2,814,350 shares of the company’s stock, valued at approximately $19,644,163. The trade was a 4.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Adaptive Biotechnologies Stock Down 5.4 %

Shares of NASDAQ ADPT opened at $7.35 on Friday. The firm’s 50-day moving average price is $7.55 and its two-hundred day moving average price is $6.02. Adaptive Biotechnologies Co. has a 52-week low of $2.28 and a 52-week high of $8.95. The stock has a market capitalization of $1.08 billion, a P/E ratio of -6.74 and a beta of 1.53.

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same period in the previous year, the company earned ($0.30) EPS. As a group, equities research analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of large investors have recently bought and sold shares of ADPT. Voya Investment Management LLC lifted its holdings in Adaptive Biotechnologies by 6,121.7% in the fourth quarter. Voya Investment Management LLC now owns 2,428,710 shares of the company’s stock worth $14,560,000 after acquiring an additional 2,389,674 shares during the last quarter. Soleus Capital Management L.P. increased its stake in shares of Adaptive Biotechnologies by 168.1% in the fourth quarter. Soleus Capital Management L.P. now owns 2,983,142 shares of the company’s stock valued at $17,884,000 after purchasing an additional 1,870,393 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Adaptive Biotechnologies by 12.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company’s stock valued at $39,597,000 after purchasing an additional 834,253 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Adaptive Biotechnologies by 794.0% in the fourth quarter. Ameriprise Financial Inc. now owns 736,720 shares of the company’s stock valued at $4,417,000 after purchasing an additional 654,309 shares during the period. Finally, Clearline Capital LP acquired a new stake in shares of Adaptive Biotechnologies in the third quarter valued at approximately $3,147,000. Institutional investors own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ADPT. The Goldman Sachs Group increased their price target on shares of Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price target (up previously from $7.00) on shares of Adaptive Biotechnologies in a research report on Thursday, February 20th. Finally, Scotiabank increased their price target on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.10.

Check Out Our Latest Analysis on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Read More

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.